Document is current
Any future updates will be listed below
-
Authors
Suzuki, Satoshi
Yokota, Tomoya https://orcid.org/0000-0001-7327-7949
Notsu, Akifumi
Hamauchi, Satoshi
Fushiki, Kunihiro
Oshima, Kotoe
Ohba, Akihiro
Kawakami, Takeshi
Tsushima, Takahiro
Yasui, Hirofumi
Yamazaki, Kentaro
Onozawa, Yusuke
Mukaigawa, Takashi
Tsubosa, Yasuhiro
Ogawa, Hirofumi
Onoe, Tsuyoshi
- License Information
-
More Information
Article History
Received: 19 March 2025
Accepted: 12 June 2025
First Online: 25 June 2025
Declarations
:
: Tomoya Yokota serves as an advisor to Merck Biopharma, MSD, Rakuten Medical, and Astellas Pharma and has received lecture fees from Merck Biopharma; Ono Pharmaceutical Co., Ltd.; Bristol-Myers Squibb; AstraZeneca; Chugai Pharmaceutical Co., Ltd., MSD, Eli Lilly Japan, and Eisai. Satoshi Hamauchi has received lecture fees from Ono Pharmaceutical Co., Ltd. Yusuke Onozawa has received lecture fees from Novartis Pharma. Kunihiro Fushiki has received Ono pharmaceutical Co., Ltd., Bristol-Meyers Squibb Co., and MSD Co., Ltd. Takahiro Tsushima has received lecture fees from Taiho Pharmaceutical Co., Ltd., Ono pharmaceutical Co., Ltd., Bristol Meyers Squibb Co., and MSD. Kentaro Yamazaki has received research funding from Esai., Pfizer., and Ono Pharmaceutical Co., Ltd., and has received lecture fees from Chugai Pharmaceutical Co., Ltd., Takeda, Eli Lilly, Taiho Pharmaceutical Co., Ltd., Merck biopharma, Yakult, Ono pharmaceutical Co., Ltd., Bristol-Myers Squibb. Akihiro Ohba serves as an advisor to Jazz and received lecture fees from Yakult, Ono, Eisai, Taiho, AstraZeneca, Guardant and MSD, and received research funding from Chugai, Novartis, DaiichiSankyo and MSD. Satoshi Suzuki, Akifumi Notsu, Kotoe Oshima, Takeshi Kawakami, Hirofumi Yasui, Takashi Mukaigawa, Yasuhiro Tsubosa, Hirofumi Ogawa, Tsuyoshi Onoe, have no conflict of interest.
: The study was approved by the Institutional Review Board of Shizuoka Cancer Center (approval num-ber: J2024-113-2024-1-3).
